Medgenics Reports Open Market Purchase of Common Stock by Chairman of the Board

Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that on December 2, 2013, was informed by Dr. Sol Barer, Medgenics’ Chairman of the Board of Directors, that he purchased 20,000 shares of common stock on the open market on that day at an average price of $6.5890 per share.

Following this purchase, Dr. Barer now owns 92,000 shares of common stock, which represents approximately 0.5 percent of the total issued shares of common stock. Dr. Barer, directly or through trusts for the benefit of Dr. Barer and his family, also has the right to purchase up to 1,315,000 shares of common stock pursuant to options previously granted (in aggregate Dr. Barer’s shares of common stock and options represent 1,407,000 shares of common stock which represent approximately 7.6 percent of the Company’s total issued shares of common stock).

This announcement is being made pursuant to the London Stock Exchange’s AIM Rules for Companies admitted to trading on the AIM market.

About Medgenics

Medgenics is developing and commercializing Biopump(TM), a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia, hepatitis, among others. For more information, please visit www.medgenics.com.

Medgenics, Inc.John Leaman, [e-mail] Marie Fields, [e-mail]@LHA_IR_PRorAbchurch CommunicationsJoanne Shears / Jamie Hooper / Harriet Rae+44 207 398 [e-mail] Securities (NOMAD & Broker)Jonathan Senior / Giles Balleny+44 207 710 7617